These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 24205256)

  • 21. Occult nodal metastasis in patients with non-small cell lung cancer at clinical stage IA by PET/CT.
    Park HK; Jeon K; Koh WJ; Suh GY; Kim H; Kwon OJ; Chung MP; Lee KS; Shim YM; Han J; Um SW
    Respirology; 2010 Nov; 15(8):1179-84. PubMed ID: 20573058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of integrated positron emission tomography and computed tomography in the assessment of nodal spread in cases with non-small cell lung cancer.
    Tasci E; Tezel C; Orki A; Akin O; Falay O; Kutlu CA
    Interact Cardiovasc Thorac Surg; 2010 Feb; 10(2):200-3. PubMed ID: 19933240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective preoperative mediastinal lymph node staging by integrated positron emission tomography-computerised tomography in patients with non-small-cell lung cancer.
    Perigaud C; Bridji B; Roussel JC; Sagan C; Mugniot A; Duveau D; Baron O; Despins P
    Eur J Cardiothorac Surg; 2009 Oct; 36(4):731-6. PubMed ID: 19632852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors for predicting the occult nodal metastasis in T1-2N0M0 NSCLC patients staged by PET/CT: potential value in the clinic.
    Li L; Ren S; Zhang Y; Guan Y; Zhao J; Liu J; Wang Q; Chen G; Chen H; Xiang J; Fu X
    Lung Cancer; 2013 Aug; 81(2):213-7. PubMed ID: 23664030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ratio of Lymph Node to Primary Tumor SUV on PET/CT Accurately Predicts Nodal Malignancy in Non-Small-Cell Lung Cancer.
    Mattes MD; Moshchinsky AB; Ahsanuddin S; Rizk NP; Foster A; Wu AJ; Ashamalla H; Weber WA; Rimner A
    Clin Lung Cancer; 2015 Nov; 16(6):e253-8. PubMed ID: 26163919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Limited predictive value of dual-time-point F-18 FDG PET/CT for evaluation of pathologic N1 status in NSCLC patients.
    Kim SJ; Kim YK; Kim IJ; Kim YD; Lee MK
    Clin Nucl Med; 2011 Jun; 36(6):434-9. PubMed ID: 21552019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of integrated positron emission tomography and computed tomography accuracy in detecting lymph node metastasis in patients with adenocarcinoma vs squamous cell carcinoma.
    Billè A; Okiror L; Skanjeti A; Errico L; Arena V; Penna D; Ardissone F; Pelosi E
    Eur J Cardiothorac Surg; 2013 Mar; 43(3):574-9. PubMed ID: 22689182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Density and SUV ratios from PET/CT in the detection of mediastinal lymph node metastasis in non-small cell lung cancer].
    Shao T; Yu L; Li Y; Chen M
    Zhongguo Fei Ai Za Zhi; 2015 Mar; 18(3):155-60. PubMed ID: 25800571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is FDG-PET/CT used correctly in the combined approach for nodal staging in NSCLC patients?
    Simsek FS; Comak A; Asik M; Kuslu D; Balci TA; Ulutas H; Koroglu R; Kekilli E; Akatli A; Elmali F; Yalcin NC; Akyol H
    Niger J Clin Pract; 2020 Jun; 23(6):842-847. PubMed ID: 32525121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Node/aorta and node/liver SUV ratios from (18)F-FDG PET/CT may improve the detection of occult mediastinal lymph node metastases in patients with non-small cell lung carcinoma.
    Kuo WH; Wu YC; Wu CY; Ho KC; Chiu PH; Wang CW; Chang CJ; Yu CT; Yen TC; Lin C
    Acad Radiol; 2012 Jun; 19(6):685-92. PubMed ID: 22459646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence of occult mediastinal node involvement in cN0 non-small-cell lung cancer patients after negative uptake of positron emission tomography/computer tomography scan.
    Gómez-Caro A; Garcia S; Reguart N; Arguis P; Sanchez M; Gimferrer JM; Marrades R; Lomeña F
    Eur J Cardiothorac Surg; 2010 May; 37(5):1168-74. PubMed ID: 20116273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of false-negative and false-positive diagnoses of lymph node metastases in non-small cell lung cancer patients staged by integrated (18F-)fluorodeoxyglucose-positron emission tomography/computed tomography: A retrospective cohort study.
    Kaseda K; Watanabe K; Asakura K; Kazama A; Ozawa Y
    Thorac Cancer; 2016 Jul; 7(4):473-80. PubMed ID: 27385991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic accuracy of virtual 18F-FDG PET/CT bronchoscopy for the detection of lymph node metastases in non-small cell lung cancer patients.
    Herbrik M; Treffert J; Geiger B; Riegger C; Hartung V; Rosenbaum-Krumme SJ; Forsting M; Antoch G; Heusner TA
    J Nucl Med; 2011 Oct; 52(10):1520-5. PubMed ID: 21908390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 18F-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense?
    Hellwig D; Graeter TP; Ukena D; Groeschel A; Sybrecht GW; Schaefers HJ; Kirsch CM
    J Nucl Med; 2007 Nov; 48(11):1761-6. PubMed ID: 17942814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mediastinal lymph node staging by FDG-PET in patients with non-small cell lung cancer: analysis of false-positive FDG-PET findings.
    Konishi J; Yamazaki K; Tsukamoto E; Tamaki N; Onodera Y; Otake T; Morikawa T; Kinoshita I; Dosaka-Akita H; Nishimura M
    Respiration; 2003; 70(5):500-6. PubMed ID: 14665776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The value on SUV-derived parameters assessed on
    Liao X; Liu M; Li S; Huang W; Guo C; Liu J; Xiong Y; Zhang J; Fan Y; Wang R
    BMC Med Imaging; 2023 Apr; 23(1):49. PubMed ID: 37020286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high.
    Turkmen C; Sonmezoglu K; Toker A; Yilmazbayhan D; Dilege S; Halac M; Erelel M; Ece T; Mudun A
    Clin Nucl Med; 2007 Aug; 32(8):607-12. PubMed ID: 17667432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer.
    Nakanishi K; Nakamura S; Sugiyama T; Kadomatsu Y; Ueno H; Goto M; Ozeki N; Fukui T; Iwano S; Chen-Yoshikawa TF
    BMC Cancer; 2021 Sep; 21(1):983. PubMed ID: 34474680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.
    Shim SS; Lee KS; Kim BT; Chung MJ; Lee EJ; Han J; Choi JY; Kwon OJ; Shim YM; Kim S
    Radiology; 2005 Sep; 236(3):1011-9. PubMed ID: 16014441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.